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| INTRODUCTION
Mutations in isocitrate dehydrogenase (IDH) 1 and 2 occur in the majority of diffuse infiltrating gliomas. The IDH1 R132H mutation (IDH1 mut) is present in approximately 80% of grade II-III gliomas and secondary glioblastoma that progressed from low-grade astrocytoma. 1 Mutations in IDH2 are much less common and are mutually exclusive with mutations in IDH1. IDH1 and IDH2 mutations are specific to codons that encode for arginine, an important amino acid in the catalytic domain of these enzymes. Most IDH1 mutations have been identified at the Arg132 codon (R132), and mutations in IDH2 have 2 | DEKKER Et al. been identified at the Arg140 codon (R140) and Arg172 codon (R172). 2 Glioma patients with IDH1/2 mutations have a significantly better prognosis compared with patients without these mutations. 2 IDH1 and IDH2 mutations occur early in gliomagenesis and change the metabolic function of these enzymes. IDH1 mut leads to the production of excessive amounts of the oncometabolite 2-hydroxyglutarate (2-HG) in glioma cells. 3 The identification of the mutations in IDH1 and IDH2 and their relative positive effects on the prognosis compared with IDH1 wild-type (IDH1 wt) glioma patients has increased interest in glioma metabolism in the brain.
Multiple preclinical models have provided possibilities to study the oncogenic properties of IDH1/2 mutations compared with IDH1 wt. In these models epigenetic regulation, cancer cell differentiation, and metabolism are shown to be altered. 3 The IDH1 mut induces changes in the concentration of tricarboxylic acid (TCA) cycle intermediates and lipid metabolites. 4, 5 In vitro and in vivo studies demonstrated that the inhibition of IDH1/2-mutant enzymes decreases intracellular D-2-hydroxyglutarate (D-2HG) levels and reverses epigenetic dysregulation. 6, 7 Gene expression profiles of large cohorts of glioma and acute myeloid leukemia have shown that IDH1/2 mutant tumors display a distinct gene expression profile enriched for genes expressed in progenitor cells. 8 Metabolic flux analyses have shown that IDH1 mut render tumor cells more dependent on citrate and fatty acids under hypoxia as compared with IDH1 wt cells and this metabolic reprogramming results in decreased cell growth of IDH1 mut cells upon hypoxia. 9 By quantitative PCR the RNA expression of the enzymes part of the aerobic glycolysis and the TCA cycle were previously studied. The RNA expressional changes were found in the enzymes of the TCA cycle (increased) and aerobic glycolysis (LDHA decreased and LDHB increased). 10 More recently, a relationship between the IDH1 mut and lactate and glutamate dependency in glioma has been proposed. 11, 12 Based on targeted RNA sequencing of a large series of metabolic enzymes, it was shown that enzymes transporting glutamate and lactate into the cell and enzymes converting lactate and glutamate into α-ketoglutarate are upregulated in IDH1 mut gliomas. 11 It was suggested that IDH1 mut gliomas depend on lactate and glutamate as metabolic substrates to alleviate metabolic stress as a result of defective isocitrate processing. 11 In this study we validate previously obtained RNA expression data at the protein level and in addition studied the pentose phosphate pathway, TCA cycle, aerobic glycolysis, glutaminolysis, fatty acid metabolism, GABA shunt, and amino acid catabolism. To perform the proteomics mapping of the pathways, FFPE tissue samples of astrocytomas, oligodendrogliomas and GBMs were investigated. The samples were analyzed using both data-dependent analysis (DDA) and targeted mass spectrometry. First, data-dependent LC-MS analyses were performed to obtain a general overview of the abundance of proteins in the samples and to identify the most prominent differences in metabolic enzymes between IDH1 mut and wildtype tumors. Subsequently, the DDA data were used to develop a targeted semiquantitative multiplex method for 64 proteins related to the various metabolic pathways to obtain insight in the metabolic consequences of the IDH1 mutation. We observed that in IDH1 mut gliomas the enzymes of the aerobic glycolysis, glutaminolysis, and amino acid catabolism were most affected.
| MATERIALS AND METHODS
Unless otherwise noted, all chemicals were purchased from Sigma-Aldrich (Saint Louis, MO) and all solvents were purchased from Biosolve (Valkenswaard, The Netherlands).
| Samples
FFPE tissue samples of surgically resected gliomas from 48 patients were used. All these gliomas are classified based on the most recent guidelines provided by WHO. 13 The set included 18 astrocytomas (IDH1 R132H and TP53 mutated), 11 oligodendroglioma (IDH1 R132H and 1p/19q loss), and 19 GBM (IDH1 wt). Additional patient characteristics can be found in Table 1 
| Nano-LC data-dependent mass spectrometry measurements
Samples were analyzed by nano-LC (Ultimate 3000RS, Thermo Fisher Scientific, Germering, Germany) coupled to a Q Exactive HF mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). The samples were analyzed with the same method and settings as described previously. 14 The LC-MS/MS proteomics data was deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD016697.
| PRM measurements
PRM analyses were performed on the same nano-LC Orbitrap Q Exactive HF system as the DDA measurements. A shorter 30 minutes gradient is used on the nano-LC system under similar LC conditions as for the DDA measurements. A quadrupole isolation window of 0.6 m/z units, an AGC target of 1 × 10 6 ions, a maximum fill time of 120 ms, and an Orbitrap resolving power of 60,000 at 200 m/z were used. A normalized collision energy (NCE) of 27% was used for all peptides together with a retention time window of 4 minutes for each peptide. Eventually, the results for all proteins were evaluated and for each protein the two best performing peptides were selected. Targeted MS/MS methods could be successfully developed for 117 peptides belonging to 64 proteins (see Table S1 ). It was not possible to analyze all targets in a single method with the required sensitivity and retention time window. For this reason different methods were created, all containing a subset of the targeted peptides. The LC-MS/MS PRM proteomics data was deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD016698.
| Data processing and analysis DDA
MaxQuant 1.6.1.0 (http://www.coxdo cs.org/doku. php?xml:id=maxqu ant:start ) was used to analyze the DDA data; default settings were used unless indicated otherwise. All raw files were loaded and the human subset of the uniprot_ sprot_2015-10 database was selected; Homo sapiens species restriction; 20,194 sequences, a maximum of two miss cleavages, oxidation as a variable modification of methionine, carbamidomethylation as a fixed modification of cysteine, and trypsin was set as enzyme. The label free quantitation option with matching between runs was used. The quantitative values for all identified protein groups were further analyzed in Perseus 1.6.1.2 (http://www.coxdo cs.org/doku.php?xml:id=perse us:start ). The data were annotated, log2 transformed, and imputation (replace value from normal distribution) was applied for missing values. Subsequently, hierarchical clustering and statistical analyses were performed to generate both heat maps and volcano plots.
| Data processing and analysis

PRM data
The PRM data were analyzed using Skyline version 3.5.0.9320 MacCoss Lab Software, Seattle, WA (https ://skyli ne.gs.washi ngton.edu/labke y/proje ct/home/softw are/Skyli ne/begin.view); fragment ions for each targeted mass were extracted and peak areas were integrated. Each fragment ion was visually inspected for interference and only fragment ions without interference in the integrated area were used and summed for further analyses. For all peptides, the areas were exported to Excel and correlation plots of peptides from the same protein were created. The values for all targeted proteins were imported in Perseus where the same analyses were performed as mentioned above for the DDA data.
| RESULTS
The LC-MS analyses of 18 astrocytomas (IDH1 R132H and TP53 mutated), 11 oligodendroglioma (IDH1 mut and 1p/19q loss), and 17 GBM (IDH1 wt) resulted in the identification of 1,509 protein groups. A hierarchical clustering of this dataset yielded two main clusters largely overlapping with the IDH1 status ( Figure 1 ). The first cluster consisted of all but one GBM sample (all IDH1 wt), and two IDH1 mut samples (one oligodendroglioma and one astrocytoma). The other main cluster consisted of the rest of the samples with the IDH1 mut (gliomas graded 2 and 3), while one GBM IDH1 wt was present. The tumor samples harboring the co-deletion of 1p/19q (defining oligodendroglioma) were not discerned.
Twenty-eight proteins with functions in glycolysis, pentose phosphate pathway, TCA cycle, aerobic glycolysis, glutaminolysis, fatty acid metabolism, GABA shunt, and catabolism of amino acids appeared to be differentially expressed between the IDH1 mut and IDH1 wt group (Figure 2 ). To more precisely map qualitative and quantitative differences in abundance between the two groups, a targeted PRM mass spectrometry method was developed for 70 selected proteins related to these pathways. The relative quantity of 64 of these 70 proteins could be determined by PRM. For 53 proteins the relative quantity was based on two peptides; for the other 11 proteins quantitation was based on a single peptide. The normalization of the data was performed on UV intensity and could be validated based on actin abundance. The actin abundance between the IDH1 wt group and the IDH1 mut group was not statistically significant. In the IDH1 wt group two outliers with a significant lower abundance of actin (ACTC1) were observed and these samples were excluded from the analyses.
Of the 64 proteins analyzed by PRM, the abundance of 48 was significantly different between the IDH1 mut and IDH1 wt sample group when applying an FDR correction of 0.05 ( Figure 3 and Table 2 ). The ratio of the quantified enzymes between IDH1 mut and IDH1 wt sample group is shown in a scheme of the glycolysis, pentose phosphate pathway, TCA cycle, and the glutaminolysis metabolic pathways (Figure 4 ). The largest shifts in the abundance of enzymes between tumors with and without IDH1 mutation are observed in the glutaminolysis and aerobic glycolysis ( Figure 5 ). The ratios between LDHA and LDHB (enzymes that are involved in pyruvate conversion into lactate and lactate into pyruvate, respectively) and the transporters that import and export lactate (SLC16A3 and SLC16A7, respectively) are shown in Figure 5A . The ratios of these enzymes indicate that LDHB and SLC16A7 are higher in abundance in contrast to LDHA and SLC16A3 in the IDH1 mut group. This indicates that lactate import and its conversion in pyruvate is increased in IDH1 mut gliomas if one assumes that the abundance of these enzymes is associated with the concentration of their substrates and products. Figure 6 shows the abundances of enzymes relating to the GABA shunt, fatty acid metabolism, valine, leucine, and isoleucine degradation (ABAT (GABA shunt)); ECHS1 and MLYCD (fatty acid metabolism); and BCKHA, BCKHB, and HIBCH (valine, leucine, and isoleucine degradation). The levels of these enzymes, except MLYCD, were significantly elevated in IDH1 mut gliomas. For MLYCD, a regulator of fatty acid metabolism, no difference was observed between the two groups. 
| DISCUSSION
Previously, we showed that RNA expression levels of aerobic glycolysis and the TCA-cycle enzymes change in IDH1 mut compared with IDH1 wt glioma. 10 In this study we confirmed these changes on the protein level. In addition, we included a number of connecting pathways to obtain a more complete view of the metabolic effects of these changes. To this end proteins of glycolysis, pentose phosphate pathway, aerobic glycolysis, fatty acid metabolism, GABA shunt, and catabolism of amino acids were included in our analyses. The most dominant changes between IDH1 mut and IDH1 wt gliomas were observed in enzymes and transporter proteins related to aerobic glycolysis and glutaminolyses. These observations confirm the previous findings at the RNA level [10] [11] [12] and strengthen the theory that both glutamate and lactate are imported and converted into α-ketoglutarate in IDH1 mut gliomas, to decrease metabolic stress caused by the mutation. [10] [11] [12] The increased import of lactate in IDH1 mut glioma cells results in a lower intracellular pH of tumor cells. Intracellular pH is tightly regulated in the cytoplasm within a narrow pH range (7.1-7.2) and is controlled by proton pumps and transporters. 15 Carbonate ions (HCO − 3 ) and Na + are the main extracellular ions that compensate for changes in pH. 16 One of the most significant changed proteins in relation to the IDH1 mut appeared to be SLC4A4. This protein is a transporter of Na + and HCO − 3 into the cell and regulates intracellular pH. 17 The increase of SLC4A4 in IDH1 mut cells is a mechanism to correct intracellular pH, in accordance with the increased import of lactate into IDH1 mut glioma cells.
Changes in glutaminolysis in relation to cancer are not unique to the IDH1 mut and have been reported in relation to various cancer types. 18 A number of oncogenes and tumor suppressors like c-MYC, KRAS, and mTOR enhance or inhibit gene expression of enzymes involved in glutaminolysis. 18, 19 In most tumors the Warburg effect (aerobic glycolysis) causes an increased lactate production and an extracellular export of lactate. Our data and findings of Lenting and co-workers indicate that in IDH1 mut gliomas lactate is actively imported into the cell in contrast to the Warburg effect. This results in metabolic changes specific to IDH1 mut gliomas and tailored to the tumor microenvironment in which large amounts of both glutamate and lactate are present. 20, 21 In both IDH1 mut glioma tissues and glioma cell culture models with the IDH1 mutation, a decrease in both glutamate and lactate levels is reported. 22, 23 These observations confirm our data and support an increased conversion of both lactate and glutamate into glioma cells with the IDH1 mut. A lack of significant changes in abundance of glycolysis enzymes corroborates with our gene expression data and the findings of Lenting and co-workers. 11 The glucose transporter (SLC2A3) and hexokinase 2 (HK2) were found downregulated in glioma samples with the IDH1 mut. We observed a decrease in protein level of the glucose transporter (SLC2A1), not the (SLC2A3) variant. A potential reason for discrepancies of our data from the transcriptomic data is the influence of non-tumor cells. The presence of erythrocytes or stromal cells in the glioma tissue samples could potentially influence the measured values to some extent. The influence of non-tumor cells on SLC2A1 abundance could be significant as SLC2A1 is highly abundant in fully matured erythrocytes and brain endothelial cells. GBM samples are more vascularized than lower-grade tumors and could for this reason contain more erythrocytes and endothelial cells. The abundance of hexokinase variants, HK1 and HK2, was increased in IDH1 mut glioma. Higher levels of HK1 abundance in low-grade gliomas is associated with normal oxidative respiration and this is indicative of a decrease in aerobic glycolysis. 24 The data indicate that lactate is imported in IDH1 mut brain tumor cells. Lactate is used for the production of pyruvate which is shuttled into the TCA cycle resulting in an increase in oxidative respiration. Oppermann et al have already shown that extracellular pyruvate can fuel the TCA cycle. 25 In cell culture experiments of U87 (IDH1 wt) cells, it was observed that glucose can be replaced by pyruvate. In these cells, pyruvate is imported and the TCA-cycle intermediates citrate, α-ketoglutarate, and succinate are increased, indicative of the utilization of extracellular pyruvate in the TCA cycle. In addition, in vivo experiments have shown that extracellular lactate may be used as an energy source in the human brain. 26 Expression levels of HK2 increase with glioma grade and the highest RNA expression and protein levels are found in GBM. 24, 27, 28 However, we were unable to confirm this by proteomics. In GBM cell lines it was shown that knocking down HK2 results in inhibition of the aerobic glycolysis leading to an increase in normal oxidative respiration and a decrease in lactate production. HK2 is crucial for the Warburg effect, increasing aerobic glycolysis. Our findings corroborate this observation and indicate that aerobic glycolysis is increased in the IDH1 wt glioma, in contrast to IDH mut glioma.
Lenting and co-workers showed that the GABA shunt is upregulated in IDH1 mut glioma. 11 ALDH5A1 is one of the proteins with the largest difference in abundance between IDH1 wt and IDH mut gliomas in the DDA analyses. ALDH5A1 converts succinic semi-aldehyde into succinate and is as such part of the GABA shunt. In addition, two other enzymes of the GABA shunt, DCE1 and ABAT, were investigated. For DCE1 we were not able to obtain quantitative data, while for ABAT we observed a significant increase in IDH1 mut gliomas indicating that the GABA shunt is upregulated. The increase in the GABA-shunt protein ABAT, which introduces additional succinate to the TCA cycle, explains the increased levels of the TCA-cycle enzymes that further process succinate. Aldehyde dehydrogenase 6 (ALDH6A1) is involved in the valine and thymine catabolism and we found a significant change in abundance in relation to the IDH1 mutation in the DDA analysis. 29 For this reason, amino acid catabolism was investigated in our targeted analyses. The enzymes involved in valine, leucine, and isoleucine catabolism (ECHS1, BCKHA, BCKHB, and HIBCH) were all significantly higher in abundance in IDH1 mut glioma samples, confirming the increase in amino acid catabolism. Glutamate and α-ketoglutarate play central roles in the catabolism of these amino acids. Proline catabolism is affected and both OAT and ALDH4A1 levels are increased, indicating that proline is converted into glutamate. In addition, the transporters of glutamate, alanine, serine, cysteine, and threonine (SLC1A2, SLC1A3, and SLC1A4) are increased. Taken together, this makes it likely that amino acid catabolism is increased for anaplerotic feeding of the TCA cycle. In addition, the presented data indicate that in IDH1 mut gliomas, compensation mechanisms are being activated to produce extra TCA-cycle metabolites to keep the TCA cycle active. It is, however, striking that the glycolysis route that fuels the TCA cycle is not increased (the glucose importer SLC2A3 RNA expression is even decreased 11 ). The obstructed catabolism of glucose in IDH1 mut gliomas was reported before. 11 in an IDH1 R132H patient-derived xenograft (PDX) it was shown that glucose is scarcely used as the carbon source for either α-ketoglutarate or 2-hydroxy-glutarate, indicative of the use of alternative carbon sources for the production of these metabolites to fuel the TCA-cycle. 30 Recently by pH and oxygen-sensitive MRI imaging of glioma patients, large differences in the tumor microenvironment of IDH1 wt and mut gliomas are observed. The authors suggest that these changes indicate that in IDH1 mut tumors the aerobic glycolysis is less active and the TCA cycle is more active which is in agreement with our findings. 31 Our data and previously acquired RNA expression data are all an indirect read-out of the metabolome. A direct measurement of the metabolome itself could potentially be more accurate. The disadvantages of a metabolomics study are that fresh-frozen tissues are required. In addition, metabolites are often involved in different chemical reactions which make it difficult to identify the exact reaction in which F I G U R E 4 Overlay of protein abundance data with metabolic pathways of the glycolysis, pentose phosphate pathway, TCA cycle, and glutaminolysis. The red arrows indicate an enzymatic reaction and the purple arrows represent transport of a metabolite over the cell membrane. The number next to each protein in the metabolic map represents the ratio between the IDH1 wt group and IDH1 mut group. A red asterisk indicates that the difference between the two groups is significant based on the volcano plot analyses with an FDR correction of 0.05 based on 250 randomizations of the data. The glutaminolysis and the aerobic glycolysis appear to be affected mostly by the IDH1 mut | 9 DEKKER Et al.
F I G U R E 5 Abundance plots of the aerobic glycolysis and glutaminolyses based on PRM analyses. Abundance plots for panel (A) aerobic
glycolysis and panel (B) glutaminolyses. In addition to the abundance plots of LDHA, LDHB, SLC16A3, and SLC16A7, the ratio between LDHA and LDHB and between SLC16A3 and SLC16A7 are displayed (panel A). The ratios indicate that predominantly in the IDH1 mut group lactate is transported into the cell and converted into pyruvate. The importer of glutamate (SLC1A2) and GLUD1 and GLUD2 (enzymes that convert glutamate into α-ketoglutarate) is increased in the IDH1 mut group (panel B). In all plots, the mean and SEM (standard error of the mean) are indicated for both groups, statistical differences (t-test) are indicated by asterisk's (**P-value < .001, ***P-value < .0001) changes occur. The protein content of a sample is usually less effected by sample collection procedures and can be extracted from FFPE material of which large collections are mostly available. Furthermore, enzymes catalyze very specific reactions; often (iso-)forms exist which are specific for a cellular compartment (mitochondrial, cytosolic) or tissue type. This information cannot be extracted from a metabolomics study and intra-and extracellular concentrations of metabolites cannot be distinguished. For these reasons we have chosen a proteomics approach, although this represents an indirect way to measure enzymatic activity. In this respect, we note that in an earlier study it was shown that RNA expression could be used as a surrogate to observe differences in the metabolism. 32 As enzymes themselves are one step closer to the metabolome, their abundances should better represent the activity of metabolic processes. Our findings, however, need to be confirmed on the metabolic level, the lack of IDH1 mutant cellular and preclinical models and the appropriate biological context of the existing models makes it difficult to translate such findings to the patient situation. 33 The altered metabolic processes probably largely depend on the microenvironment of the tumor cells resulting in rather large assumptions to translate findings from cell culture models to the in vivo situation. For this reason models that are closer to the in vivo situation, for instance, glioma PDX models have an advantage. 34 A relative large panel of inhibitors that target enzymes or transporters of the glutamate metabolism exist. 19 The inhibitors open possibilities to target these enzymes in metabolic flux experiments in IDH1-mutated glioma PDX models to validate the findings in this study. In addition are improvements made in MRI imaging which allow in vivo metabolic profiling of tumors. 31, 35 In conclusion, in IDH1 mut glioma significant differences in specific enzymes of the glutaminolysis and aerobic glycolysis are found. This proteomics study confirms and extends on earlier findings at the RNA expression level. The observations in IDH mut glioma are independent of tumor grade or molecular subtype of the tumor and affect predominantly the abundance of enzymes related to glutaminolysis. Based on these results we propose that the import of glutamate into IDH1 mut cells is increased as well as F I G U R E 6 Abundance plots based on PRM analyses. Abundance plots based on PRM analyses for ECHS1 and MLYCD (fatty acid metabolism) panel (A) for BCKHA, BCKHB, and HIBCH (valine, leucine, and isoleucine degradation) panel (B), and for ABAT (GABA shunt) panel (C). For all plots in the three panels the IDH1 mut group is compared with the IDH1 wt group. Statistical differences (t-test) are indicated by asterisks (***P-value < .001). All proteins were found to be statistically different except for MLYCD. For all analysis the mean value with the SEM is indicated | 11 DEKKER Et al.
the conversion of glutamate into α-ketoglutarate. Enzymes that convert proline, valine, leucine, and isoleucine into glutamate are also increased. Furthermore, the transport of lactate and the enzymes involved in the subsequent conversion into α-ketoglutarate are increased. The increased intake of lactate results in intracellular acidification which is most likely compensated by an increase in the bicarbonate transporter (SLC4A4). The metabolism seems to be rewired to produce additional α-ketoglutarate to preserve the TCA cycle as a survival mechanism for IDH1 mut gliomas. Further validation including metabolic flux experiment is required. The presented data aids in a better understanding of the role of the IDH1 mutation in glioma metabolism and can generate ideas how drugs can be designed to interfere with the specific energy requirements in IDH1 mut and IDH1 wt glioma.
